RSS Feed ALL

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

about 8 hours ago

66% of patients with scalp psoriasis and 77% with genital psoriasis treated...

Johnson & Johnson expands efforts to champion the nursing workforce globally

1 day ago

New social impact platform J&J CareCommunity aims to collaboratively help address global...

Johnson & Johnson’s New “Oncology Care Index” Highlights the Growing Divide Between Cancer Innovation and Implementation in Clinical Practice

4 days ago

73% of surveyed HCPs say there’s a gap between the availability of...

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

4 days ago

TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement...

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

4 days ago

Data from the QUASAR long-term extension study demonstrate more than 70% of...

Johnson & Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

9 days ago

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive...

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference

11 days ago

Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

13 days ago

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across...

Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

13 days ago

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved...

Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting

14 days ago

Omny-IRE data demonstrated the investigational OMNYPULSE™ Platform achieved 100% acute success and...

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA

18 days ago

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data...

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

23 days ago